Phase 3 Study of XEN1101 in Primary Generalized Tonic-Clonic Seizures

Clinical Trial Information

Trial Contact: Melendez, Thomas L, Colon Morales, Veronica J, Carlo, Charlene S, Mondragon, Diana, Monserrate, Francheska

IRB No: S26.152.07

Principal Investigator: Zaher, Naoir, MD

Phase: N/A

Age Group: CHILDADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT05667142

Objective

To assess the effect of XEN1101 versus placebo on reducing PGTCS frequency in subjects with PGTCS.

Share:

Related Clinical Trials

A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination with Rilvegostomig in Participants with High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04)
An Interventional Phase III, Open-Label, Randomized Study to Evaluate Efficacy and Safety of PF-08634404 in Combination with Chemotherapy versus Pembrolizumab in Combination with Chemotherapy in Adult Participants with Advanced or Recurrent Mismatch Repair Proficient Endometrial Cancer
Study of a New Device for Severe Asthma (PULSAR)
A Randomized, Open-Label Phase III Study of Azenosertib versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression